You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Estrogen Receptors in Non Small Cell Lung Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers14010080

This entry highlights that exogenous and endogenous sources of estrogens in the human body.  Estrogen associated receptors ERs, GPERs, EGFRs and orphan nuclear receptors ERRs. Role of estrogens and associated receptors in normal lung physiology and NSCLC complications. Potential of using anti-estrogen molecules, alone or in combination with ER/GPER/ EGFR/ERR inhibitors as NSCLC treatment regimen.

non-small cell lung cancers (NSCLCs) Pre-/Post-Menopausal Women Estrogens Estrogen Receptors (ERs) G Protein Coupled ER (GPERs) Epidermal Growth Factor Receptors

1. Background

Exogenous and endogenous estrogens and associated receptors modulate signaling pathways with biochemical events implicated in non-small cell lung cancer (NSCLC) manifestation. The diversity of biochemical interactions initiated by estrogens is rigorous, regulated via distinct estrogen-associated receptors. While estrogen receptor beta (ERβ) is overexpressed in 60–80% of NSCLCs irrespective of gender, the recognition of transmembrane G-protein-coupled estrogen receptor (GPER) creates several interfaces of estrogen-interception-driven aggressive NSCLC manifestation. There is still room for understanding the crux of ER–EGFR (epidermal growth factor receptor) interactions considering the recent clinical trials revealing a synergistic anti-NSCLC response. 

2. Role of Estrogen Receptors in Non-Small Cell Lung Cancer Complication

To implicate ERs in the complications of NSCLCs, it is essential to determine that the NSCLC tissues are exposed to estrogens either through localized enhanced aromatase expression or via sufficient circulatory estrogens being synthesized and secreted in the gonads. Exposure of the human body to exogenous estrogens is also possible either through administration of synthetic estrogens/phytoestrogens orxenoestrogenic agents. Since both genomic or non-genomic actions of estrogens involve interactions with ERs or other associated receptors (e.g., GPER/EGFR), detecting the expression level of these receptors in the NSCLC tissues may be crucial. Indeed, aromatase activities have been detected in NSCLC cell lines as well as ~86% of tumors [1]. A number of studies including one by the Mollerup group reported the ER prevalence in lung tumors and NSCLC cell lines [2]. Additionally, a relationship of the hormonal status in the cancer-affected tissues with the expression index of ERs has been established. Of note, it is well known that premenopausal women generate large contingents of estrogens as compared to postmenopausal women and men of all age groups. A comparative analysis of ER expression extent in cancer patients, vis-à-vis age/gender group of pre- and postmenopausal women and men, revealed the highest ER expression intensity in the premenopausal women. In this study, the men cancer patients exhibited a minimal ER expression, suggesting a critical role of either circulating or local tissue level of estrogens in the ER expression [3]. Additionally, overexpression of ERs is detected in lung adenocarcinoma. Of the two ER types, the ERβ is more abundant in lung cancer. Studies have reported an ERβ overexpression in 60–80% of tumors, irrespective of gender [4]. In a noted effort, Kawai and associates explained the differential ERα detection pattern in NSCLC samples using an ERα antibody (Ab) raised against either a full-length or an N-terminus or a C-terminus ERα protein. The Ab against the C-terminus ERα region detected a predominantly cytoplasm-localized protein compared to the one raised against the N-terminus of the protein. The investigators predicted that in NSCLC, ERα is N-terminal-deleted and lacks the nuclear localization signal [5]. In a similar study on the prevalence of ERα splice variants, ERα36 was reported in NSCLC specimens, while wild-type ERα was minimally expressed. The results of this study claim that in normal lungs, the wild-type ERα is quasi-absent [6]. In comparison, both in normal physiology as well as in cultured NSCLC cells, the ERβ is predominantly localized within the nucleus [7][5]. A number of studies including that of Baik and colleagues described the ERβ nuclear localization as a more reliable prognosis factor contrary to that of the cytoplasmic ERβ expression [8]. Studies also claimed that the cytoplasmic and the nuclear ERβ co-expression were correlated with a low survival rate compared to the one without co-expression [9]. The ERs are also localized in the plasma membrane [10][11]. Studies by Gao and teammates claimed the ER involvement in NSCLC progression by modulating the membrane receptor signaling network [12]. It is predicted that the localization of ERs in the specific cellular compartment including plasma membrane, cytoplasm and/or nucleus may have a distinct function and affect the prognosis differentially via a genomic or non-genomic pathway. The ERs expressed by lung bronchial epithelial as well as NSCLC cells respond transcriptionally to E2/17β-estradiol [13][14][15]. In a Kras-activated and p53-deletion-induced lung adenocarcinoma mice model, administration of E2/17β-estradiol promoted the tumor progression. In this experimental mice model, male and ovariectomized female mice respond likewise in response to17β-estradiol administration [16]. The poorer clinical outcomes observed in NSCLC patients may be related to the proliferative as well as survival responses to 17β-estradiol. A number of studies documented the specific cell signaling molecules and associated pathways involved in the 17β-estradiol dependent proliferation, survival and growth of in vitro cultured NSCLC cell lines and tumor xenografts [17][14][4][18]. However, there is a lot of controversy regarding beneficial versus adverse effects of HRT in the human body [19][20]. Similarly, the role of ERs in NSCLC remains controversial, and the mechanisms of action of ERs in NSCLC complications are not conclusive. There is no consensus on whether ERβ expression plays a role in survival. Some studies have suggested a protective effect of ERβ nuclear expression [21][22][23], which may only be significant in men [23]. It is possible that the presence of nuclear ERβ confers a hormonal dependence for growth rather than on the other more aggressive oncogenic pathways, leading to a comparatively better survival. A number of comprehensive review articles described various aspects of ERs in the NSCLC complication [24][25].

3. Efficacy of Anti-Estrogen and Anti-Estrogen Receptor Molecules against Non-Small Cell Lung Cancers

Aromatase inhibitors that include irreversible steroid inhibitors/non-steroidal inhibitors (e.g., anastrozole, letrozole, etc.) and selective ER modulators (SERMs, e.g., tamoxifen, a competitive inhibitor with equal ERα and ERβ affinity) or selective ER downregulators (SERDs, e.g., fulvestrant/ICI182780, a pure anti-ER molecule with equal affinity for ERα and ERβ which degrades both ERα and ERβ) are used against estrogen/ER-dependent cancers. The efficacy of these molecules against NSCLC complication was examined by in vitro cell culture and animal model experiments including xenograft and ER knockout mice models and clinical studies involving NSCLC patients. Details of the estrogen activities in lung cancer complication, particularly in women, have been recently reviewed [26][27]. In cell culture experiments using A549 NSCLC cells, it was shown that lowering the estrogen concentration inhibited the A549 cell’s growth [28]. Another significant in vitro study revealed that aromatase inhibitors such as letrozole significantly decreased cell proliferation while exemestane reduced tumor growth and increased cell apoptosis, alongside inhibiting cell migration and invasion [29]. The efficacy of the SERD molecules such as fulvestrant was also examined in the in vitro cell culture based experiments and tumor xenograft mouse model. The results of these studies show significant inhibition of 17β-estradiol-induced NSCLC (cell lines) grown in culture and as tumor xenografts. In this study, the combined activity of anti-ER and anti-EGFR molecules emerged more efficacious pertaining to the anti-NSCLC activities [14]. A number of similar experimental studies focused on the efficiency of fulvestrant in NSCLC suppression [30][31][32]. Data presented by Wang and colleagues showed that dexamethasone suppresses the growth of NSCLC cell line A549 injected xenograft tumors via inducing estrogen sulfotransferases and decreasing estradiol levels in tumor tissues, suggesting that dexamethasone may be used as an anti-estrogenic agent for the NSCLC treatment [33]. Clinical observational studies consisting of 6500 breast cancer survivors subjected to anti-estrogen therapy showed lower subsequent lung cancer mortality [34]. In another similar study consisting of 2320 patients, a strong anti-estrogen therapy and lung cancer motility correlation was observed [35]. More recently, three separate and independent clinical trials have been conducted to evaluate the anti-estrogen/anti-ER therapeutic efficacy toward lung cancer [36][37][38]. Based on the results, it is predicted that, in the future, ER detection in NSCLC could be considered reliable treatment recourse for women. Comprehensive review articles discussed the estrogens and their receptors in influencing the development as well as microenvironment of lung cancers and the significance of clinical studies exploring the anti-estrogen/anti-ER therapy usefulness against lung cancers (Table 1) [39][40].
Table 1. Current progress of clinical trials aimed toward using estrogen-expression-targeted non-small cell lung cancer treatment.
Table
Clinical Trial Registry Primary Objective of the Trial Phase of Study, Tumor Stage and Current Status Findings Published (Ref.)
NCT01556191 Evaluating an EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib and an EGFR-TKI-anti-oestrogen (erlotinib, fulvestrant) combined potency in women with advanced-stage non-squamous lung cancer Phase I, stage IV lung cancer, completed Improved outcome
[41]
NCT00100854 Evaluation of synergistic fulvestrant delivery with erlotinib for the non-small cell lung cancer (NSCLC) treatment Phase II, stage IIIB or IV non-small cell lung cancer, completed Improved outcome
[42]
NCT02666105 Evaluation of adding exemestane therapy in postmenopausal women suffering from NSCLC while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab or nivolumab) Phase II, advanced stage NSCLC, ongoing Improved outcome
[43]
NCT01664754 Determining the safety and tolerability of escalating exemestane doses on being co-delivered with pemetrexed (pemetrexed disodium) and carboplatin in postmenopausal womensuffering from NSCLC Phase I, stage IV non-squamous NSCLC, ongoing Combination is safe and well-tolerated, response rate correlates with tumor aromatase expression
[44]
NCT02751385 Screening the effect of nintedanib on the (ethinylestradiol + levonorgestrel) pharmacokinetics in NSCLC patients Phase I, all NSCLC patients, completed No findings published todate
NCT00576225 Screening the effect of paclitaxel poliglumex (CT-103)/carboplatin versus paclitaxel/carboplatin for women NSCLC sufferers Phase III, sufferers having >25 pg·mL−1 estradiol, completed CT-103 did not provide superior survival over the paclitaxel-carboplatin for first-line treatment of NSCLC patients, results were comparable for progression-free and overall survival [45]
NCT03099174 Ascertaining a safe dosage of xentuzumab in combination with abemaciclib with or without hormonal therapies in lung and breast cancer Phase I, no stage distinction, ongoing Findings not yet published
NCT00592007 Screening the impact of adding fulvestrant to erlotinib in NSCLC patients Phase II, stage IIIB or IV, concluded [46]
NCT00932152 Fulvestrant and anastrozole (aromatase inhibitor) as consolidation therapy in postmenopausal women NSCLC sufferers Phase II, advanced stage NSCLC, concluded [47]
NCT01594398 Assessing the food effect on entinostat pharmacokinetics in NSCLC sufferers (ENCORE110) Phase I, no stage distinction, completed No findings published, study listed from [39]
AM2013-4664 Evaluation of erlotinib antitumor activity in NSCLC on fulvestrant inclusion in the patients received > 1 chemotherapy regimen Phase II, advanced state NSCLC patients [48]
 

References

  1. Skjefstad, K.; Grindstad, T.; Khanehkenari, M.R.; Richardsen, E.; Donnem, T.; Kilvaer, T.; Andersen, S.; Bremnes, R.M.; Busund, L.T.; Al-Saad, S. Prognostic relevance of estrogen receptor alpha, beta and aromatase expression in non-small cell lung cancer. Steroids 2016, 113, 5–13.
  2. Mollerup, S.; Jorgensen, K.; Berge, G.; Haugen, A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37, 153–159.
  3. Rodriguez-Lara, V.; Pena-Mirabal, E.; Baez-Saldana, R.; Esparza-Silva, A.L.; Garcia-Zepeda, E.; Cerbon Cervantes, M.A.; Diaz, D.; Fortoul, T.I. Estrogen receptor beta and CXCR4/CXCL12 expression: Differences by sex and hormonal status in lung adenocarcinoma. Arch. Med. Res. 2014, 45, 158–169.
  4. Hershberger, P.A.; Vasquez, A.C.; Kanterewicz, B.; Land, S.; Siegfried, J.M.; Nichols, M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res. 2005, 65, 1598–1605.
  5. Kawai, H. Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer. World J. Clin. Oncol. 2014, 5, 1020–1027.
  6. Pelekanou, V.; Anastasiou, E.; Bakogeorgou, E.; Notas, G.; Kampa, M.; Garcia-Milian, R.; Lavredaki, K.; Moustou, E.; Chinari, G.; Arapantoni, P.; et al. Estrogen receptor-alpha isoforms are the main estrogen receptors expressed in non-small cell lung carcinoma. Steroids 2019, 142, 65–76.
  7. Stabile, L.P.; Davis, A.L.; Gubish, C.T.; Hopkins, T.M.; Luketich, J.D.; Christie, N.; Finkelstein, S.; Siegfried, J.M. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002, 62, 2141–2150.
  8. Baik, C.S.; Eaton, K.D. Estrogen signaling in lung cancer: An opportunity for novel therapy. Cancers 2012, 4, 969–988.
  9. Wang, Z.; Li, Z.; Ding, X.; Zhirong, S.; Zhentao, L.; Tongtong, A.; Jianchun, D.; Jia Zhong, J.; Wu, M.; Zhao, J.; et al. ER-beta localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. Sci. Rep. 2015, 5, 11392.
  10. Filardo, E.J.; Quinn, J.A.; Graeber, C.T. Evidence Supporting a Role for GPR30, an Orphan Member of the G-Protein-Coupled Receptor Superfamily, in Rapid Estrogen Signaling. The Identities of Membrane Steroid Receptors; Springer: Boston, MA, USA, 2003.
  11. Thomas, P.; Pang, Y.; Filardo, E.J.; Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146, 624–632.
  12. Gao, X.; Cai, Y.; Zhuo, W.; He, W.; Cao, S.; Xu, R.; Chen, H. Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: A systems biology perspective. J. Transl. Med. 2019, 17, 308.
  13. Li, P.; Wang, J.; Wu, D.; Ren, X.; Wu, W.; Zuo, R.; Zeng, Q.; Wang, B.; He, X.; Yuan, J.; et al. ERRα is an aggressive factor in lung adenocarcinoma indicating poor prognostic outcomes. Cancer Manag. Res. 2019, 11, 8111–8123.
  14. Stabile, L.P.; Lyker, J.S.; Gubish, C.T.; Zhang, W.; Grandis, J.R.; Siegfried, J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced anti-proliferative effects. Cancer Res. 2005, 65, 1459–1470.
  15. Ivanova, M.M.; Mazhawidza, W.; Dougherty, S.M.; Klinge, C.M. Sex differences in estrogen receptor sub-cellular location and activity in lung adenocarcinoma cells. Am. J. Respir. Cell Mol. Biol. 2010, 42, 320–330.
  16. Hammoud, Z.; Tan, B.; Badve, S.; Bigsby, R.M. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr. Relat. Cancer 2008, 15, 475–483.
  17. Pietras, R.J.; Marquez, D.C.; Chen, H.W.; Tsai, E.; Weinberg, O.; Fishbein, M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005, 70, 372–381.
  18. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491–1494.
  19. Cagnacci, A.; Venier, M. The controversial history of hormone replacement therapy. Medicina 2019, 55, 602.
  20. Lobo, R.A. Hormone-replacement therapy: Current thinking. Nat. Rev. Endocrinol. 2017, 13, 220–231.
  21. Wu, C.T.; Chang, Y.L.; Shih, J.Y.; Lee, Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J. Thorac. Cardiovasc. Surg. 2005, 130, 979–986.
  22. Schwartz, A.G.; Prysak, G.M.; Murphy, V.; Lonardo, F.; Pass, H.; Schwartz, J.; Brooks, S. Nuclear estrogen receptor beta in lung cancer: Expression and survival differences by sex. Clin. Cancer Res. 2005, 11, 7280–7287.
  23. Skov, B.G.; Fischer, B.M.; Pappot, H. Oestrogen receptor β over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008, 59, 88–94.
  24. Li-Han, H.; Nei-Min, C.; Shu-Huei, K. Estrogen, estrogen receptor and lung cancer. Int. J. Mol. Sci. 2017, 18, 1713.
  25. Pinton, G.; Manzotti, B.; Balzano, C.; Moro, L. Expression and clinical implications of estrogen receptors in thoracic malignancies: A narrative review. Thorac. Dis. 2021, 13, 1851–1863.
  26. Rodriguez-Lara, V.; Costa, M.R.A. An overview of lung cancer in women and the impact of estrogen in lung carcinogenesis and lung cancer treatment. Front. Med. 2021, 8, 600121.
  27. Musial, C.; Zaucha, R.; Kuban-Jankowska, A.; Konieczna, L.; Belka, M.; Gammazza, A.M.; Baczek, T.; Cappello, F.; Wozniak, M.; Gorska-Ponikowska, M. Plausible role of estrogens in pathogenesis, progression and therapy of lung cancer. Int. J. Environ. Res. Public Health 2021, 18, 648.
  28. Koutras, A.; Giannopoulou, E.; Kritikou, I.; Antonacopoulou, A.; Evans, T.R.; Papavassiliou, A.G.; Kalofonos, H. Antiproliferative effect of exemestane in lung cancer cells. Mol. Cancer 2009, 8, 109.
  29. Giannopoulou, E.; Siatis, K.E.; Metsiou, D.; Kritikou, I.; Papachristou, D.J.; Kalofonou, M.; Koutras, A.; Athanassiou, G.; Kalofonos, H.P. The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration. Biochim. Biophys. Acta 2015, 1853, 328–337.
  30. Weinberg, O.K.; Marquez-Garban, D.C.; Fishbein, M.C.; Goodglick, L.; Garban, H.J.; Dubinett, S.M.; Pietras, R.J. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 2005, 65, 11287–11291.
  31. Tang, H.; Liao, Y.; Zhang, C.; Chen, G.; Xu, L.; Liu, Z.; Fu, S.; Yu, L.; Zhou, S. Fulvestrant-mediated inhibition of estrogen receptor signaling slows lung cancer progression. Oncol. Res. 2014, 22, 13–20.
  32. Miki, Y.; Abe, K.; Suzuki, S.; Suzuki, T.; Sasano, H. Suppression of estrogen actions in human lung cancer. Mol. Cell Endocrinol. 2011, 340, 168–174.
  33. Wang, L.J.; Li, J.; Hao, F.R.; Yuan, Y.; Li, J.Y.; Wei, L.; Tian-Yan, Z. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen. Acta Pharmacol. Sin. 2016, 37, 845–856.
  34. Bouchardy, C.; Benhamou, S.; Schaffar, R.; Verkooijen, H.M.; Fioretta, G.; Schubert, H.; Vinh-Hung, V.; Soria, J.C.; Vlastos, G.; Rapiti, E. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 2011, 117, 1288–1295.
  35. Lother, S.A.; Harding, G.A.; Musto, G.; Navaratnam, S.; Pitz, M.W. Antiestrogen use and survival of women with non-small cell lung cancer in Manitoba, Canada. Horm. Cancer 2013, 4, 270–276.
  36. Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer. Available online: https://clinicaltrials.gov/Bct2/show/NCT00592007?term=estrogen&;rslt=With&cond=Lung+Cancer&draw=2&rank=1 (accessed on 20 December 2020).
  37. Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women with Advanced Non-Small Cell Lung Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT00932152?term=estrogen&;rslt=With&cond=Lung+Cancer&draw=2&rank=2 (accessed on 20 December 2020).
  38. Alisertib in Adults with Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies. Available online: https://clinicaltrials.gov/ct2/show/NCT01045421?term=estrogen&;rslt=With&cond=Lung+Cancer&draw=2&rank=5 (accessed on 20 December 2020).
  39. Rodriguez-Lara, V.; Hernandez-Martinez, J.-M.; Arrieta, O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J. Thorac. Dis. 2018, 10, 482–497.
  40. Smida, T.; Bruno, T.C.; Stabile, L.P. Influence of Estrogen on the NSCLC microenvironment: A comprehensive picture and clinical implications. Front. Oncol. 2020, 10, 137.
  41. Traynor, A.M.; Schiller, J.H.; Stabile, L.P.; Kolesar, J.M.; Eickhoff, J.C.; Dacic, S.; Hoang, T.; Dubey, S.; Marcotte, S.M.; Siegfried, J.M. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009, 64, 51–59.
  42. Garon, E.B.; Sadeghi, S.F.F.; Kabbinavar, K.L.; Reckamp, D.C.; Marquez-Garban, L.P.; Stabile, L.; Goodglick, S.M.; Dubinett, J.M.; Siegfried, R.; Pietras, J. Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2008, 26, 19091.
  43. Collins, I.M.; Nicholson, S.A.; O’Byrne, K.J. A lung cancer responding to hormonal therapy. J. Thorac. Oncol. 2010, 5, 749–750.
  44. Langer, C.J.; O’Byrne, K.J.; Socinski, M.A.; Mikhailov, S.M.; Leśniewski-Kmak, K.; Smakal, M.; Ciuleanu, T.E.; Orlov, S.V.; Dediu, M.; Heigener, D.; et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J. Thorac. Oncol. 2008, 3, 623–630.
  45. Young, P.A.; Márquez-Garbán, D.C.; Noor, Z.S.; Moatamed, N.; Elashoff, D.; Grogan, T.; Romero, T.; Sasano, H.; Saito, R.; Rausch, R.; et al. Investigation of combination treatment with an aromatase inhibitor exemestane and carboplatin-based therapy for postmenopausal women with advanced NSCLC. JTO Clin. Res. Rep. 2021, 2, 100150.
  46. Garon, E.B.; Siegfried, J.M.; Stabile, L.P.; Young, P.A.; Marquez-Garban, D.C.; Park, D.J.; Patel, R.; Hu, E.H.; Sadeghi, S.; Parikh, R.J.; et al. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer 2018, 123, 91–98.
  47. Xu, R.; Shen, H.; Guo, R.; Sun, J.; Gao, W.; Shu, Y. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomed. Pharmacother. 2012, 66, 384–389.
  48. Garon, E.S.; Siegfried, J.M.; Dubinett, S.M.; Elashoff, R.M.; Park, D.J.; Parikh, R.J.; Patel, R.; Hu, E.H.; Reckamp, K.L.; Adams, B.; et al. Results of TORI-L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced nonsmall cell lung cancer (NSCLC). In Proceedings of the 104th Annual Meeting of the American, Philadelphia, WA, USA, 6–10 April 2013.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Radhashree Maitra
View Times: 768
Revisions: 4 times (View History)
Update Date: 10 Jan 2022
Table of Contents
Academic Video Service
Feedback